PXL065 is a new chemical entity derived from pioglitazone, which has shown to retain NASH efficacy without triggering peroxisome proliferator-activated receptor (PPAR)-g-related side effects in ...

“We are pleased with these results in likely-NASH patients; they confirm that target engagement in patients has been achieved and that some of the effects observed with PXL770 in various preclinical ...

NASH has a poor prognosis. It currently accounts for 10% of liver transplantations conducted in the USA and is predicted to soon become the most common indication for liver transplantation.

Although the first wave (the companies with drugs at Phase-3) is already at the finish line, the effectiveness indicators of these drugs are far from being strong. Comparison of Phase-2 drugs pursuing ...

A research team from Japan investigated whether a noninvasive measurement of tissue strain has a potential usefulness for management of nonalcoholic steatohepatitis (NASH). The results showed that ...

During the 2021 Society of Toxicology (SOT) Annual Meeting, researchers from Swiss-based InSphero AG and from US-based PharmaNest Inc have presented a novel key technology to help drug developers in ...

In the 2020 April 21 issue of Journal of Hepatology, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that a new insight into the ...